Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
Xi M, Zhu J, Zhang F, Shen H, Chen J, Xiao Z, Huangfu Y, Wu C, Sun H, Xia G.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2024.116709 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för FK-866. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
35 träffarDesign of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
Lu T, Chen F, Yao J, Bu Z, Kyani A, Liang B, Chen S, Zheng Y, Liang H, Neamati N, Liu Y.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.4c00193Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
Yin C, Jia S, Yang X, Wu L.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2024.116444Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
Wen F, Gui G, Wang X, Qin A, Ma T, Chen H, Li C, Zha X.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c02482Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.
Velma GR, Krider IS, Alves ETM, Courey JM, Laham MS, Thatcher GRJ.
J Med Chem · research support, non-u.s. gov't; review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.3c02112HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.
Yue K, Sun S, Liu E, Liu J, Hou B, Qi K, Chou CJ, Jiang Y, Li X.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2024.116127Synthesis, Optimization, and Structure-Activity Relationships of Nicotinamide Phosphoribosyltransferase (NAMPT) Positive Allosteric Modulators (N-PAMs).
Shen Z, Ratia K, Krider I, Ackerman-Berrier M, Penton C, Musku SR, Gordon-Blake JM, Laham MS, Christie N, Ma N, Fu J, Xiong R, Courey JM, Velma GR, Thatcher GRJ.
J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.3c01406Discovery of Dual Function Agents That Exhibit Anticancer Activity via Catastrophic Nicotinamide Adenine Dinucleotide Depletion.
Fu Y, Huang Y, Zhou C, Li X, Dong G, Huang M, Ding J, Sheng C.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01362Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
Zhang P, Wang W, Guo M, Zhou L, Dong G, Xu D, Sheng C.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2023.129393Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
Fratta S, Biniecka P, Moreno-Vargas AJ, Carmona AT, Nahimana A, Duchosal MA, Piacente F, Bruzzone S, Caffa I, Nencioni A, Robina I.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115170Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.
Wang K, Ye K, Zhang X, Wang T, Qi Z, Wang Y, Jiang S, Zhang K.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01954Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer.
Bi K, Cheng J, He S, Fang Y, Huang M, Sheng C, Dong G.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01990Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.
Bai JF, Majjigapu SR, Sordat B, Poty S, Vogel P, Elías-Rodríguez P, Moreno-Vargas AJ, Carmona AT, Caffa I, Ghanem M, Khalifa A, Monacelli F, Cea M, Robina I, Gajate C, Mollinedo F, Bellotti A, Nahimana A, Duchosal M, Nencioni A.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114504Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
Zhang K, Wang K, Zhang X, Qian Z, Zhang W, Zheng X, Wang J, Jiang Y, Zhang W, Lu Z, Hao H, Jiang S.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c00077Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Zhang W, Zhang K, Yao Y, Liu Y, Ni Y, Liao C, Tu Z, Qiu Y, Wang D, Chen D, Qiang L, Li Z, Jiang S.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.113022Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
Wu Y, Wang L, Huang Y, Chen S, Wu S, Dong G, Sheng C.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.9b00407Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Ozgencil F, Eren G, Ozkan Y, Guntekin-Ergun S, Cetin-Atalay R.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.115217Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Travelli C, Aprile S, Mattoteia D, Colombo G, Clemente N, Scanziani E, Terrazzino S, Alisi MA, Polenzani L, Grosa G, Genazzani AA, Tron GC, Galli U.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.111576Controlling cellular distribution of drugs with permeability modifying moieties.
Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.
Medchemcomm · research-article; journal article · DOI 10.1039/c8md00412aDiscovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
Zhang K, Ni Y, Chen J, Tu Z, Wu X, Chen D, Yao H, Jiang S.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2019.04.013Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
Chen W, Dong G, Wu Y, Zhang W, Miao C, Sheng C.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.7b00414Fragment-based discovery of a potent NAMPT inhibitor.
Korepanova A, Longenecker KL, Pratt SD, Panchal SC, Clark RF, Lake M, Gopalakrishnan SM, Raich D, Sun C, Petros AM.
Bioorg Med Chem Lett · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.bmcl.2017.12.023Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G, Chen W, Wang X, Yang X, Xu T, Wang P, Zhang W, Rao Y, Miao C, Sheng C.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.7b00467SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML, Heyman HR, Clark RF, Sorensen BK, Doherty GA, Hansen TM, Frey RR, Sarris KA, Aguirre AL, Shrestha A, Tu N, Woller K, Pliushchev MA, Sweis RF, Cheng M, Wilsbacher JL, Kovar PJ, Guo J, Cheng D, Longenecker KL, Raich D, Korepanova AV, Soni NB, Algire MA, Richardson PL, Marin VL, Badagnani I, Vasudevan A, Buchanan FG, Maag D, Chiang GG, Tse C, Michaelides MR.
Bioorg Med Chem Lett · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.bmcl.2017.06.018Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
Travelli C, Aprile S, Rahimian R, Grolla AA, Rogati F, Bertolotti M, Malagnino F, di Paola R, Impellizzeri D, Fusco R, Mercalli V, Massarotti A, Stortini G, Terrazzino S, Del Grosso E, Fakhfouri G, Troiani MP, Alisi MA, Grosa G, Sorba G, Canonico PL, Orsomando G, Cuzzocrea S, Genazzani AA, Galli U, Tron GC.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.6b01392Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
Zak M, Yuen PW, Liu X, Patel S, Sampath D, Oeh J, Liederer BM, Wang W, O'Brien T, Xiao Y, Skelton N, Hua R, Sodhi J, Wang Y, Zhang L, Zhao G, Zheng X, Ho YC, Bair KW, Dragovich PS.
J Med Chem · journal article · DOI 10.1021/acs.jmedchem.6b00697Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Bai J, Liao C, Liu Y, Qin X, Chen J, Qiu Y, Qin D, Li Z, Tu ZC, Jiang S.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.6b00324Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
Clark DE, Waszkowycz B, Wong M, Lockey PM, Adalbert R, Gilley J, Clark J, Coleman MP.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2016.04.039Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Giannetti AM, Zheng X, Skelton NJ, Wang W, Bravo BJ, Bair KW, Baumeister T, Cheng E, Crocker L, Feng Y, Gunzner-Toste J, Ho YC, Hua R, Liederer BM, Liu Y, Ma X, O'Brien T, Oeh J, Sampath D, Shen Y, Wang C, Wang L, Wu H, Xiao Y, Yuen PW, Zak M, Zhao G, Zhao Q, Dragovich PS.
J Med Chem · journal article · DOI 10.1021/jm4015108Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
Christensen MK, Erichsen KD, Olesen UH, Tjørnelund J, Fristrup P, Thougaard A, Nielsen SJ, Sehested M, Jensen PB, Loza E, Kalvinsh I, Garten A, Kiess W, Björkling F.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm4009949